A batch of varieties is expected to enter the 2020 version of the national health insurance.

Pharmaceutical Network August 10, recently, the State Health Insurance Administration released the "2020 National Health Insurance Drug Catalog Adjustment Work Programme (draft for comments)" and public lying for comments.
the 2020 revision criteria for the transfer to the catalogue are clearer than the adjustment plan announced in 2019: inclusion in the list of new drugs in clinical needs, encouraging generic drug catalogs or encouraging research and development to declare the list of children's drugs, and the approval of the State Drug Administration for listing by December 31, 2019.
to this, there are research institutions combed some not in the 2019 national health insurance catalog, but in the above list of drugs and corresponding production, research and development companies, from the statistical results, biological monoto-resistance, foreign research and development, China Biopharmaceuticals, Jiangsu Hausen and other some of the reserve varieties.
in addition, GBI Health, according to the GBI SOURCE database, compiled 20 or will enter the 2020 national health insurance negotiations of the list of drugs, including more biological monoto-resistance, including Iloyu monotonica, daremu monoto-resistance and Paboli bead monotonica and other varieties.
variety is followed by the purchase price of the symbol in hospitals in China, France, Germany, the United Kingdom and Australia, with the red part being the lowest price.
(Picture source: GBI HEALTH) Industry has the view that from the adjustment rules of the Health Insurance Bureau, its focus on clinical necessity, centralized procurement, innovative drugs and local drug use, drug economics has become the main standard.
drugs that are underperforming or have serious side effects have been largely excluded from the list, while products that account for a large proportion of health-care drugs in catalogue spending will be included in the scope of the adjustment compensation standard.
to some extent, the adjustment of this standard will promote the clinically urgently needed new drugs to accelerate the release of drugs, while the clinical effect is not clear drugs quickly exit the market, to achieve rational drug use and cage for birds.
local drug use, ushered in a turn of the above-mentioned document clear, the province added varieties have the opportunity to enter the national version of health insurance: before December 31, 2019, into 5 (including) the latest provincial version of the medical insurance drug catalog drugs.
, but the main active ingredients are included in the "first batch of state key state key monitoring of rational drug use of drugs" except.
in the previous Minet network combing, in 2019 China's public medical institutions terminal 37 over 1 billion yuan of local health insurance catalog varieties, there are 35 varieties of provinces to add more than 5. After
removed the key monitoring varieties, Dizzosin injection, injection with erythropoietin, injection of cephalosporine sodium tatnabine, hydrochloric acid polyrousbi star lipid injection, injection with yew alcohol lipid, injection with pentahydrodiazepine sodium, bedy blue anti-inflammatory oral liquid, injection of cephalosporine sodium, injection with thunder Bellamyn sodium, injection of inflamed ambernin, injection of cephalosporine sodium, injection with cyclophosphate adenosine, injection of cephalosporine sodium sodium supatin, large strain of red-steamed natural injection, chlorate tablets, injection of cephalosporine sodium and other varieties, supplemented provinces are more than 5, or have the opportunity to enter the 2020 version of the national health insurance.
according to incomplete statistics of the relevant media, there are 5 varieties in more than 20 provinces to add, namely, ginseng glucose, safflower pills, enosasar, cephalosporine tatan, glycoglutinator;
Jiangsu Pharmaceutical Co. , Ltd. retail procurement manager Jia Xiaoqing to Saibai Lan said: in accordance with the local addition of varieties removal principle, within three years the original place to add all the clear, if not expand the national catalog varieties, will bring certain problems: on the one hand, medical institutions and patients medical treatment habits changes, self-funding burden increased;
therefore, whether from the perspective of medical insurance, production enterprises or patients, to the current national drug catalog varieties, but also can not reach the "rich standards" to meet the patient's medication.
so make rules, so that the rules of the variety into the health care catalog is also inevitable. Guo Xinfeng, a partner at Nanjing Le Pharma Venture Investment Management Co., Ltd.,
, put forward a similar view: there are plugs and dredging - the State Health Insurance Administration has closed loopholes, but the provincial health insurance supplements reflect regional clinical needs to a certain extent, there should be new channels to solve the historical legacy, there may be up to 3 years of green channel.
he further explained that "five provinces have one", meaning that the five provinces add more products into the new version of the health insurance catalog of the opportunity to increase, while the five provinces to add the following products or will lose access to the national health insurance green channel, need to be access to health insurance by other means.
for pharmaceutical companies, Guo Xinfeng believes that according to the product strength (just need edifying products, non-essential products) and marketing promotion capacity comprehensive assessment of whether the need for health insurance access, such as O medicine, K drug market has not yet cultivated mature, has not yet met the price reduction conditions, difficult to meet the requirements of a 50% reduction in access negotiations, even if not included in the national health insurance, but still maintain strong growth, is expected to become a 5 billion heavy bomb products.
and for rheumatic immune products, such as Adamu monotoreactor, a variety of targets and biosimilars fierce competition, patients in the efficacy and price between the choice is more, non-access to health insurance means self-rejecting patients, so in 2019 Adamu monoto-resistance on the basis of 7820 yuan on a substantial price reduction of 84%, to 1290 yuan negotiationsuccessful successful access to health insurance.
in general, according to the document, before December 31, 2019, enter the latest version of the provincial medical insurance drug catalog of drugs, before the opportunity to return to enter the national medical insurance drug catalog, the state is using past data, the current drug companies do not have any provincial number of remedial measures.
exclusive varieties, or benefit more? Data from the Drug Intelligence Network show that more than 40% of the exclusive varieties in the local medical insurance supplements, while the proportion of traditional Chinese medicine is relatively high, and more than half of the varieties in the supplementary catalogues of Guizhou, Anhui, Jiangsu, Jilin and Gansu provinces are exclusive varieties.
for pharmaceutical companies, if the exclusive varieties into health insurance, no competition, there is no pressure to reduce prices, can quickly achieve market volume.
Guo Xinfeng to Saeber Lan analysis: if there are similar products in the general directory of medical insurance, only different dosage forms, it is very likely to be included in the regular catalog, access to health insurance;
it's worth noting that, while it's included in the scope of the Medicare drug adjustment, it's just? Chances? Ultimately, whether or not to get into health care depends on the variety itself.
"Is the general direction of selected varieties in accordance with the rules in line with? Clinical demand for drugs, fund affordability? Principle.
on the national supplement, the biggest change is the "health insurance functional positioning" change, "extensive" access way to become history, the optimization of the structure of varieties on the agenda.
principles will be given priority to return to the health care catalogue.
", Jia Xiaoqing reminded, "the proportion of traditional Chinese medicine is a special reason in it, in accordance with the April release of the "Temporary Measures for the Administration of Basic Medical Insurance Drug Use" - with independent intellectual property rights of innovative Chinese medicine may be good, but conventional chinese medicine may not be good, because it is difficult to achieve clinical necessity, safe and effective, reasonable price and other basic conditions.
" province added more than 10 varieties, these drugs are expected to enter the health insurance (the statistical data is large, inevitable omission, hope everyone understand) the following varieties, in the new version of the medical insurance catalog drug adjustment range (Photo Source: Fengyun Medicine Talk)